When Drug Coupons End Up in the Insurer’s Pocket – A Patient’s Struggle with Copay Accumulator Policies

Larry Gruber has spent the better part of a decade counting on a glossy coupon card that Amgen— the maker of Enbrel— mailed him each year. The card, worth several thousand dollars, was supposed to slide into his health‑plan’s deductible, push him toward his out‑of‑pocket maximum, and then let the insurance cover the rest of the pricey monthly injections.

For most of that time, the system worked almost too well. By February, Gruber had hit his annual out‑of‑pocket cap, and the rest of the year the drug came to him at no cost. He could focus on training his clients in Wilton Manors, Florida, without worrying that his arthritis medication would drain his paycheck.

Everything changed when he switched to Oscar Health’s HMO in 2026. Instead of letting the Amgen coupon count toward his deductible, Oscar kept the card for itself and told Gruber he had to pay the full $7,700‑plus price tag until he satisfied the plan’s $10,600 out‑of‑pocket limit on his own.

“It feels like the real insult is that they’re taking money that’s meant to help you,” Gruber said, eyes downcast. “I had been saving for a house, and now I’m forced to dip into that savings just to stay healthy.”

What Oscar is doing isn’t an isolated quirk; it’s part of a growing trend known as “copay accumulator” programs. In these arrangements, insurers treat manufacturer‑provided coupons as if they never existed, refusing to apply them toward deductibles, co‑pays, or out‑of‑pocket maximums. The practice has been spreading over the last ten years as insurers hunt for ways to curb spiraling prescription‑drug costs, according to consulting firm Avalere Health.

Patient advocates warn that the people most harmed by these programs are the heavy‑use patients who rely on specialty drugs for chronic conditions—think autoimmune diseases, multiple sclerosis, diabetes, HIV, and cancer. When treatment is delayed or interrupted, the downstream medical expenses can dwarf the amount saved by the insurer.

Oscar Health’s Florida market president, Matt Choffin, declined to discuss Gruber’s specific case. He did, however, defend the broader policy, saying copay accumulators help keep monthly premiums down and manage rising drug‑spending pressures.

Drug manufacturers push back, arguing that insurers and pharmacy‑benefit managers use these tactics to steer patients toward cheaper, often generic, alternatives, even when none exist. In Gruber’s case, there is no generic version of Enbrel, and the alternative would be a return to painful, stiff joints that would jeopardize his career as a fitness coach.

Adding to the confusion, many consumers can’t even tell whether their plan employs a copay accumulator. The language in plan documents is dense, and insurers rarely flag the policy in plain sight. Critics say this opacity lets insurers “double‑dip”—they keep the coupon money and still collect the patient’s full cost share.

“They’re collecting the money twice and they’re hurting patients,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Why does it matter if the money comes from a drug company, a parent, or the patient himself? The insurer still ends up with it.”

It’s worth noting that not every type of health coverage permits such programs. Medicare, Medicaid, and high‑deductible health plans paired with Health Savings Accounts are barred from using copay assistance because federal anti‑kickback rules forbid manufacturers from influencing patient choices with financial incentives.

But for the roughly 40 % of Affordable Care Act marketplace plans that do employ accumulators—nearly half of all plans sold in Florida, according to a review by The AIDS Institute—the impact is real and growing.

For Gruber, the math is stark. Without the coupon, he faces a $10,600 out‑of‑pocket ceiling, meaning he must spend roughly $3,000 on other covered services just to get back to where the coupon would have placed him. That cash, he says, was earmarked for a down‑payment on a house he hopes to buy next year.

The broader debate remains: Should insurers be allowed to keep drug‑maker coupons that were explicitly designed to ease patients’ financial burden? Or does the practice simply mask the true cost of specialty drugs and shift it onto the patient, potentially worsening health outcomes and inflating overall health‑care spending?

As the conversation unfolds in state legislatures and at the federal level, patients like Larry Gruber are left holding the bag—sometimes literally, as a coupon card that now sits on a desk, unused, while his prescription costs keep climbing.